Axiom Biosciences opened a Regulation Crowdfunding offering on Wefunder. The San Diego clinical-stage biotechnology company develops regenerative therapies and targeted biologic candidates. Eligible retail investors can participate in the community round.
Use of funds
Axiom plans to use the proceeds to advance its therapeutic pipeline. This includes a planned Phase 2 development program. Funds may also support work exploring a possible future public offering in Hong Kong.
Company background
Axiom was founded in 2018 and is headquartered in San Diego. It previously operated as Cytonus Therapeutics. The company is advancing programs from rare pediatric conditions toward adult ischemic stroke.
Lead program
The lead regenerative medicine program targets severe brain injuries in newborns. These include intraventricular hemorrhage and hypoxic-ischemic encephalopathy. Axiom is also developing targeted delivery technologies for biologic therapies at disease sites.
The offering is being conducted under Section 4(a)(6) of the Securities Act through Wefunder Portal LLC. The company also anticipates a conventional private financing round for institutional accredited investors. That round would aim to close after the Wefunder offering closes.